Trial · NCT01202877
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 25 mg | Complete Remission (CR) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 50 mg | Complete Remission (CR) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase II: 5-azacytidine + PKC412 | Complete Remission (CR) | 1 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 25 mg | Complete w/Incomplete Bone Marrow Recovery (CRi) | 1 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 50 mg | Complete w/Incomplete Bone Marrow Recovery (CRi) | 1 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase II: 5-azacytidine + PKC412 | Complete w/Incomplete Bone Marrow Recovery (CRi) | 4 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 25 mg | Morphologic Leukemia-Free Status (MLFS) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 50 mg | Morphologic Leukemia-Free Status (MLFS) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase II: 5-azacytidine + PKC412 | Morphologic Leukemia-Free Status (MLFS) | 6 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 25 mg | Partial Remission (PR) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase I: 5-azacytidine + PKC412 50 mg | Partial Remission (PR) | 0 | participants | |
| Participant Best Response Assessed Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 | Phase II: 5-azacytidine + PKC412 | Partial Remission (PR) | 1 | participants | |
| Overall Response (OR) Within 6 Months | Phase I: 5-azacytidine + PKC412 25 mg | 1 | participants | ||
| Overall Response (OR) Within 6 Months | Phase I: 5-azacytidine + PKC412 50 mg | 1 | participants | ||
| Overall Response (OR) Within 6 Months | Phase II: 5-azacytidine + PKC412 | 12 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01202877/results